Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)

Jones, Ronald N.; Guzmán-Blanco, Manuel; Gales, Ana Cristina; Gallegos, Belisario; Castro, Aura Lucía Leal; Martino, Marinês Dalla Valle; Vega, Silvio; Zurita, Jeannete; Cepparulo, Mario; Castanheira, Mariana

doi:10.1016/j.bjid.2013.07.002

Cited by 116 publications

(121 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NDM enzymes, like other carbapenemases, will be difficult to control, and further importation and dissemination are inevitable (1,14). NDM enzymes are already found among multiple species and in numerous countries worldwide (15)(16)(17)(18)(19)(20). Speculation that Acinetobacter pittii may be an NDM reservoir for dissemination to enteric species has been the focus of several investigations, but it still requires definitive confirmation (21).…”

Section: Discussionmentioning

confidence: 99%

Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

Biedenbach¹,

Bouchillon²,

Hackel³

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

Biedenbach¹,

Bouchillon²,

Hackel³

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…and E. coli isolates of Peru (70% and 54%, respectively) and Guatemala (69% and 59%, respectively). 7 Neonates constitute a high-risk group for developing nosocomial sepsis. Bloodstream infection rates of neonates are three to 20 times higher in developing countries than the rates of one to five per 1,000 live births reported from developed countries.…”

Section: Introductionmentioning

confidence: 99%

Molecular Characterization of Extended-Spectrum β-Lactamase-Producer Klebsiella pneumoniae Isolates Causing Neonatal Sepsis in Peru

García¹,

Astocondor²,

Rojo–Bezares³

et al. 2016

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Klebsiella pneumoniae (KP) is the most common cause of neonatal sepsis in the low-and middle-income countries. Our objective was to describe the phenotypic and molecular characteristics of extended-spectrum β-lactamase (ESBL)-producer KP in neonatal care centers from Peru. We collected 176 non-duplicate consecutive KP isolates from blood isolates of neonates from eight general public hospitals of Lima, Peru. The overall rate of ESBL production was 73.3% (N = 129). The resistance rates were higher among ESBL-producer isolates when compared with the nonproducers: 85.3% versus 12.8% for gentamicin (P < 0.01), 59.7% versus 8.5% for trimethoprim-sulfamethoxazole (P < 0.01), 45.0% versus 8.5% for ciprofloxacin (P < 0.01), and 36.4% versus 12.8% for amikacin (P < 0.01). A total of 359 β-lactamase-encoding genes were detected among 129 ESBL-producer isolates; 109 isolates (84.5%) carried two or more genes. Among 37 ESBL-producer isolates randomly selected, CTX-M-15 and CTX-M-2 were the most common ESBLs detected. Most of the isolates (92%) belonged to the group KpI. Pulsed-field gel electrophoresis showed that multiple KP clones were circulating among the eight neonatal units included.

show abstract

“…Acute bacterial skin infections are most frequently caused by Gram-positive pathogens (3,4); methicillinresistant Staphylococcus aureus (MRSA) is the predominant causative pathogen in many parts of the United States (5-7) and is endemic in Europe and other geographic regions (8)(9)(10). Current therapies for MRSA infection are associated with dosing-or administration-related complexities, a lack of oral formulations, safety issues, drug-drug interactions, and resistance (11)(12)(13)(14).…”

mentioning

confidence: 99%

Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections

Shorr

Lodise

Corey

et al. 2015

Antimicrob Agents Chemother

129

View full text Add to dashboard Cite

e Tedizolid, a novel oxazolidinone with activity against a wide range of Gram-positive pathogens, was evaluated in two noninferiority phase 3 acute bacterial skin and skin structure infection trials. The data from individual trials showed its noninferior efficacy compared to that of linezolid and a favorable tolerability profile. To evaluate potential differences, the pooled data were analyzed. The patients received 200 mg of tedizolid once daily for 6 days or 600 mg of linezolid twice daily for 10 days. Efficacy was evaluated at 48 to 72 h (primary endpoint), on days 11 to 13 (end of therapy [EOT]), and 7 to 14 days after the EOT (posttherapy evaluation). Treatment-emergent adverse events and hematologic and clinical laboratory parameters were collected. The baseline characteristics were comparable between the treatment groups: 852/1,333 (64%) patients were from North America, and the majority of infections were caused by Staphylococcus aureus. Tedizolid was noninferior to linezolid (early clinical responses, 81.6% versus 79.4%, respectively). The early responses remained relatively consistent across various host/disease factors and severity measures. Nausea was the most frequently reported adverse event (tedizolid, 8.2%; linezolid, 12.2%; P ‫؍‬ 0.02), with onset occurring primarily during the first 6 days. Fewer tedizolid than linezolid patients had platelet counts of <150,000 cells/mm 3 at the EOT (tedizolid, 4.9%; linezolid, 10.8%; P ‫؍‬ 0.0003) and during the postbaseline period through the last day of active drug visit (tedizolid, 6.4%; linezolid, 12.6%; P ‫؍‬ 0.0016). Efficacy was achieved with a 6-day once-daily course of therapy with the option of an intravenous/oral regimen, and fewer low platelet counts and gastrointestinal side effects were reported with tedizolid than with linezolid, all of which aligns well with antimicrobial stewardship principles. (These studies have been registered at ClinicalTrials.gov under registration no. NCT01170221 and NCT01421511.)

show abstract

Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)

Abstract: LATAM nations demonstrated variable levels of antimicrobial R especially among Enterobacteriaceae (β-lactamase-mediated), PSA and ACB. MRSA (48%), VRE (14%) and multidrug-R SPN were also regional therapeutic challenges.

Cited by 116 publications

References 10 publications

Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

Molecular Characterization of Extended-Spectrum β-Lactamase-Producer Klebsiella pneumoniae Isolates Causing Neonatal Sepsis in Peru

Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections

Contact Info

Product

Resources

About